The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.225
Bid: 2.20
Ask: 2.25
Change: 0.25 (11.11%)
Spread: 0.05 (2.273%)
Open: 2.25
High: 2.50
Low: 2.125
Prev. Close: 2.25
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

20 Dec 2021 13:08

RNS Number : 2300W
Genedrive PLC
20 December 2021
 

PDMR Dealing

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that it has been notified of the following transaction by Matthew Fowler, a person discharging managerial responsibilities, and his wife who is a person closely associated with him.

Following the transfer outlined below, Matthew Fowler's total beneficial interest remains unchanged at 139,457 Ordinary Shares.

This notification is made in accordance with the Market Abuse Regulation. 

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Matthew Fowler

 

 

2.

Reason for the notification

a.

Position/status

PDMR, CFO

a.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

genedrive plc

b.

LEI

213800ZYODIRZ87Y4K14

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type

of instrument

Identification code

Ordinary shares of 1.5 pence each

 

 

 

GB00B1VKB244

b.

Nature of the transaction

Transfer of shares to Alison Fowler (spouse) for nil consideration.

c.

Price(s) and volume(s)

 

 

Price £nil

 

Volume(s) 50,000 

 

 

 

 

d.

Aggregated information

·Aggregated volume

·Price

 

 

50,000

 

Nil

 

e.

Date of the transaction

2021-12-20

f.

Place of the transaction

Outside a trading venue

 

For further details please contact:

genedrive plc

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel 

finnCap (Joint Broker)

+44 (0)20 7220 500

Geoff Nash / Kate Bannatyne / Alice Lane

Walbrook PR Ltd (Media Relations & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEADAEAEKFFFA
Date   Source Headline
1st May 20202:01 pmRNSPrice Monitoring Extension
1st May 20207:00 amRNSManufacturing milestones met for SARS-CoV-2 test
29th Apr 20209:06 amRNSSecond Price Monitoring Extn
29th Apr 20209:00 amRNSPrice Monitoring Extension
28th Apr 20204:42 pmRNSSecond Price Monitoring Extn
28th Apr 20204:35 pmRNSPrice Monitoring Extension
28th Apr 20202:05 pmRNSSecond Price Monitoring Extn
28th Apr 20202:00 pmRNSPrice Monitoring Extension
27th Apr 20209:00 amRNSPrice Monitoring Extension
24th Apr 20203:30 pmRNSHolding(s) in Company
24th Apr 20207:00 amRNSDistribution agreement for AIHL test
24th Apr 20207:00 amRNSDistribution agreement for AIHL test
22nd Apr 20207:00 amRNSAppointment of Joint Broker
21st Apr 20204:41 pmRNSSecond Price Monitoring Extn
21st Apr 20204:36 pmRNSPrice Monitoring Extension
21st Apr 20202:52 pmRNSHolding(s) in Company
20th Apr 20209:05 amRNSSecond Price Monitoring Extn
20th Apr 20209:00 amRNSPrice Monitoring Extension
20th Apr 20207:00 amRNSCytiva collaboration on Coronavirus PCR Test
17th Apr 20202:06 pmRNSSecond Price Monitoring Extn
17th Apr 20202:01 pmRNSPrice Monitoring Extension
16th Apr 20202:53 pmRNSHolding(s) in Company
15th Apr 20204:41 pmRNSSecond Price Monitoring Extn
15th Apr 20204:36 pmRNSPrice Monitoring Extension
15th Apr 20202:05 pmRNSSecond Price Monitoring Extn
15th Apr 20202:00 pmRNSPrice Monitoring Extension
15th Apr 202011:05 amRNSSecond Price Monitoring Extn
15th Apr 202011:00 amRNSPrice Monitoring Extension
14th Apr 20209:06 amRNSSecond Price Monitoring Extn
14th Apr 20209:00 amRNSPrice Monitoring Extension
14th Apr 20207:01 amRNSHolding(s) in Company
14th Apr 20207:00 amRNSHolding(s) in Company
31st Mar 202011:52 amRNSHolding(s) in Company
30th Mar 20202:01 pmRNSHolding(s) in Company
30th Mar 202011:06 amRNSSecond Price Monitoring Extn
30th Mar 202011:00 amRNSPrice Monitoring Extension
25th Mar 20207:00 amRNSBusiness Update and SARS-COV-2 tests development
4th Mar 20203:33 pmRNSGrant of options
13th Feb 20209:53 amRNSHolding(s) in Company
11th Feb 20204:00 pmRNSDirector/PDMR Shareholding
6th Feb 20204:30 pmRNSHolding(s) in Company
5th Feb 20205:38 pmRNSDirector/PDMR Shareholding
5th Feb 20205:32 pmRNSDirector/PDMR Shareholding
5th Feb 20204:45 pmRNSHolding(s) in Company
5th Feb 20207:15 amEQSHardman & Co Research: genedrive plc (GDR): Western market progress but developing markets difficult
4th Feb 20204:25 pmRNSDirector/PDMR Shareholding
4th Feb 20202:06 pmRNSSecond Price Monitoring Extn
4th Feb 20202:00 pmRNSPrice Monitoring Extension
4th Feb 20207:00 amRNSHalf-year Report
15th Jan 20207:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.